Stay updated with breaking news from Ingo Mellinghoff. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In an international study co-led by UCLA, scientists have shown that a new targeted therapy drug can extend the amount of time people with a subtype of glioma are on treatment without their cancer worsening.
MONDAY, June 5, 2023 (HealthDay News) -- An experimental targeted therapy can dramatically slow the progress of common slow-growing brain cancers, a new clinical trial finds.
Vorasidenib reduced the risk of disease progression or death for certain patients with low-grade brain cancer, recent study results showed.
In an international study co-led by UCLA, scientists have shown that a new targeted therapy drug can extend the amount of time people with a subtype of glioma are on treatment without their cancer worsening. The finding suggests a possible new treatment option for people with the slow-growing but deadly brain tumor.
Treatment with the IDH1/2 inhibitor vorasidenib reduced the risk of progression or death by 61% compared with placebo for patients with grade 2 IDH-mutant glioma, according to findings from the phase 3, double-blind INDIGO trial.